Sanofi and Google forge $500 million diabetes partnership
September 12, 2016Research and Development, Sales and Marketing Alphabet, Sanofi, Verily, diabetes, google
Sanofi is set to join forces with Alphabet’s life sciences firm Verily in a $500 million partnership to develop diabetes …
PCI Pharma Services to Share Expertise at Free Serialization Forum
September 9, 2016PCI Pharma Services
Leading pharmaceutical outsourcing services provider PCI Pharma Services, in collaboration with Xytnek, Antares, and Healthcare Packaging magazine, will host a …
Gilead appoints former Roche executive
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, Roche, appointment
Gilead Sciences has hired Rogers Luo as vice president and general manager of commercial operations in China. Luo formerly served …
Kymab demonstrates promising research for HIV vaccine development
September 9, 2016Medical Communications, Research and Development HIV, Vaccine, kymab
Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the effort to develop effective vaccines …
GSK proposes biopreparedness unit to combat global outbreaks
September 9, 2016Medical Communications, Research and Development Ebola, GSK, Zika
London-based pharma giant GlaxoSmithKline has proposed the creation of a biopreparedness unit to help avert crises like those we have …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Pfizer launches legal action to block Xeljanz copies in India
September 9, 2016Medical Communications, Sales and Marketing Pfizer, Sun Pharma, Xeljanz, Zydus Cadila, rheumatoid arthritis
Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts …
FDA approves Dechra’s generic antibiotic
September 9, 2016Medical Communications, Sales and Marketing Dechra, Putney, antiobiotic, generic
Dechra has announced that the US Food and Drug Administration (FDA) has approved its generic antibiotic. The product will be …
Apple introduce stricter entry requirements for health apps
September 8, 2016Medical Communications, Research and Development Apple, Guidelines, apps, iphone, strict
Apple has toughened its stance on health and medical apps that can be bought and downloaded on the iOS App …
Retrophin announces positive Phase II results, Shkreli claims credit
September 8, 2016Research and Development Phase II, Retrophin, Shkreli, rare kidney disease
Retrophin has announced positive top-line results for trial drug sparsentan in Phase II to treat a rare kidney disorder with …
Celgene and Agios to file FDA application for “first-in-class” cancer drug
September 8, 2016Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios
According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …
Takeda begins Phase III dengue vaccine trial
September 8, 2016Research and Development Takeda, Vaccine, dengue, dengue vaccine, phase III, trial
Takeda Pharmaceuticals has announced the initiation of a global Phase III clinical trial to test its live-attenuated tetravalent dengue vaccine …
Clinical Trial Transparency
September 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trial, clinical trial transparency, transparency
Amid the global political and economic turmoil taking place, one small pharma story got much less attention than it should …
FDA to review MSD’s Keytruda as a first-line lung cancer treatment
September 7, 2016Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo
The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …
Pfizer appoints new chief scientific officer for neuroscience research
September 7, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Dr Ole Isacson has been named as the chief scientific officer at Pfizer’s neuroscience research unit. He will continue to …
Allergan CEO outlines ‘social contract with patients’
September 7, 2016Research and Development, Sales and Marketing Allergan, Brent Saunders, CEO, blog
Highlighting a recent shift in the priorities of the pharmaceutical industry, Allergan CEO and president Brent Saunders has outlined a …
Tonix tanks after Phase III failure
September 7, 2016Research and Development PTSD, fibromylagia, phase III failure, tonix, tonix pharmaceuticals
New York-based Tonix Pharmaceuticals has suffered an almost 60% fall in their share price, after the announcement that its fibromyalgia …
Allergan acquires biotech Retrosense for $60 million
September 7, 2016Research and Development, Sales and Marketing Allergan, Retrosense, acquisition
Allergan has announced that it has acquired Retrosense, a biotech focused on novel gene therapy approaches to restore vision in …
Antitrust investigation launched into Mylan and the EpiPen scandal
September 7, 2016Research and Development, Sales and Marketing Mylan, US, antitrust, epipen, investigation, lawmakers, scandal
The New York attorney general has commenced an investigation into Mylan Pharmaceuticals, after an initial review indicated that the company …
European Commission approves new RA treatment from BMS
September 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis
Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
